NovaBay Pharmaceuticals, Inc. (NYSE:NBY) has been assigned a $5.00 price target by analysts at Roth Capital in a research report issued on Monday. The firm presently has a “buy” rating on the stock. Roth Capital’s price objective would suggest a potential upside of 16.28% from the company’s current price.

NBY has been the topic of several other research reports. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Thursday, September 21st. HC Wainwright set a $6.00 price objective on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Finally, Maxim Group restated a “hold” rating on shares of NovaBay Pharmaceuticals in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $6.40.

NovaBay Pharmaceuticals (NYSE:NBY) traded down 1.15% during mid-day trading on Monday, hitting $4.30. 5,837 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $4.45 and its 200-day moving average price is $3.82. The stock’s market cap is $65.83 million. NovaBay Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $5.09.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. The firm had revenue of $4.12 million for the quarter, compared to analysts’ expectations of $4.57 million. NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%. Equities analysts expect that NovaBay Pharmaceuticals will post ($0.47) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/24/novabay-pharmaceuticals-inc-nby-given-a-5-00-price-target-by-roth-capital-analysts.html.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Analyst Recommendations for NovaBay Pharmaceuticals (NYSE:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.